A balanced review of the status T cell-based therapy against cancer by Marincola, Francesco M
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Commentary
A balanced review of the status T cell-based therapy against cancer
Francesco M Marincola*
Address: Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, 
20892, USA
Email: Francesco M Marincola* - fmarincola@mail.cc.nih.gov
* Corresponding author    
Abstract
A recent commentary stirred intense controversy over the status of anti-cancer immunotherapy.
The commentary suggested moving beyond current anti-cancer vaccines since active-specific
immunization failed to match expectations toward a more aggressive approach involving the
adoptive transfer of in vitro expanded tumor antigen-specific T cells. Although the same authors
clarified their position in response to others' rebuttal more discussion needs to be devoted to the
current status of T cell-based anti-cancer therapy. The accompanying publications review the status
of adoptive transfer of cancer vaccines on one hand and active-specific immunization on the other.
Hopefully, reading these articles will offer a balanced view of the current status of antigen-specific
ant-cancer therapies and suggest future strategies to foster unified efforts to complement either
approach with the other according to specific biological principles.
A recent commentary stirred intense controversy over the
status of anti-cancer immunotherapy. The commentary
suggested moving beyond current anti-cancer vaccines
since active-specific immunization failed to match expec-
tations [1]. Although subsequently mitigated [2-4] the
statement requires clarifications.
In the commentary the adoptive transfer of tumor anti-
gens-specific T cells was promoted in alternative to active-
specific immunization as if the two modalities were dis-
tinct biological entities rather than two extreme manifes-
tations of the same phenomenon [1]. In fact, both exploit
acquired cellular immunity in recognition of autologous
cancer cells. Active-specific immunization consistently
induces increments in circulating tumor antigen-specific T
cell  in vivo that are rarely sufficient to induced cancer
regression [5]. We have recently argued that this observa-
tion does not represent a failure of immunization but sim-
ply a successful first step among those required to induce
cancer regression [6]. In particular, circulating immuniza-
tion-induced T cells physiologically display a quiescent
phenotype close to memory C8+ T cells and require anti-
gen recall plus co-stimulation in the target tissue to
develop into activate effector cell [7]. Adoptive transfer of
tumor antigen-specific T cells combined with nonmyelo-
ablative chemotherapy and the systemic administration
of interleukin-2 relies in the administration of ex vivo acti-
vated T cells and appears to be associated with enhanced
clinical response rates at least in the subgroup of patients
in which successful expansion is possible [1,8]. Interest-
ingly, it was recently reported that persistence of adop-
tively transferred lymphocyte clonotypes significantly
correlates with cancer regression [9]. This finding suggests
that either ex vivo manipulation or in vivo conditions in
different patients may differentially influence T cell per-
sistence and, possibly, function. Interestingly, however, T
cell persistence in itself does not clearly explain therapeu-
tic effectiveness since other ex vivo expansion protocols are
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associated with long term persistence of adoptively trans-
ferred T cells which is not associated as tightly with tumor
regression as discussed by the accompanying Yee's manu-
script. In between these two extreme treatment modalities
lies the combination of active-specific immunization with
the systemic administration of interleukin-2 that has been
associated with intermediate clinical response rates [10].
Although in the absence of prospective randomized stud-
ies it remains to be confirmed whether active-specific
immunization adds to the systemic administration of
interleukin-2 alone, it is reasonable to conceive the work-
ing hypothesis that the mere presence of circulating, can-
cer-specific T cells is not sufficient to induce cancer
regression and other factors need to be added to induce
their in vivo activation as an alternative to the ex vivo acti-
vation utilized for adoptive transfer. It is, therefore, our
conclusion that the dichotomy between the two strategies
is quite arbitrary and is merely symptomatic of our lim-
ited understanding of the requirement for effective T cell
localization and activation in target tissues [6].
The surprising conclusion that anti-cancer immunization
failed to yield the results anticipated by pre-clinical and
early clinical studies [1,10-12] may be unduly pessimistic
[3]. However, the strongest argument against a premature
disposal of active-specific immunization is the recogni-
tion that our discontent comes from the naive haste in
which clinical protocols have been designed in the previ-
ous decade looking primarily at clinical end-points and
by-passing the more realistic goal of understanding the
biology of the immune response under those conditions
[6]. Rather than discarding the impressive results obtained
by immunization, we should recite an introspective mea
culpa for our failure to pay enough attention to the process
of immunization at the systemic as well as at the tumor
level [5]. In fairness, this negligence is due to the extreme
difficulty that clinical scientists confront when studying
human material and, possibly, most questions related to
the understanding of human tumor immune responsive-
ness remain answered simply because it is exceedingly dif-
ficult to analyze tumor/host interactions in the tumor-
microenvironment [13]. We have recently summarized
novel strategies that could be applied to by-pass such dif-
ficulty [14-16].
In the accompanying Point-Counter Point series pub-
lished in the Journal of Translational Medicine Craig
Slingluff and Cassian Yee engage in a balanced discussion
over the advantages and disadvantages of active specific
immunization on one side and adoptive transfer of tumor
antigen-specific T cells on the other. Future opportunities
are presented with special emphasis on the complementa-
rily and biological similarity of the two approaches. It is
hoped that lessons learned from either approach will ena-
ble better design of future clinical studies combining the
simplicity and safety of active-specific immunization with
the power of adoptive immune therapy.
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